Pelvital Archives - Medical Design Sourcing

GSK-backed venture fund APVC sees opportunities in ultrasound

Juan-Pablo Mas of APVC details the firm’s investment in EXO.

Action Potential Venture Capital, a corporate investment arm of GSK, sees therapeutic opportunities in ultrasound, according to a partner at the group.

In this week’s DeviceTalks Weekly Podcast, Action Venture partner Juan-Pablo Mas explains why APCV led the recent round in Exo, a maker of the first piezoelectric micromachined ultrasonic transducer (PMUT) portable ultrasound imaging technology.

Mas also updates listeners on the venture fund’s interest in exploring other types of technologies. And he introduces LatinxVc, a non-profit group he co-founded to create opportunities for newcomers to venture capital.

Trust Securities Managing Director Kaila Krum says Medtronic (NYSE:MDT) executives are retooling the company to keep pace with smaller, more focused competitors.

Breaking down the company’s Q1 analyst ca…

DTW Podcast: Truist’s Kaila Krum says Medtronic prepping for growth

In an interview with DeviceTalks Weekly Podcast, Truist Securities managing director Kaila Krum says Medtronic executives are retooling the company to keep pace with smaller, more focused competitors.

Breaking down the company’s Q1 call, Krum says Medtronic is seen as a company that’s too big to grow market share quickly. On the call, new CEO Geoff Martha emphasized gaining market share at one point telling investors the company would “go big or go home.”

Krum says Medtronic will pour resources into several critical areas to drive growth including soft tissue robotics, diabetes, and renal denervation.

“At a time when a lot of companies right now are forced to pull back on spending, Medtronic has been in a position where it can flex its balance sheet,” Krum said. “So they’ve been talking about investing in the pipeline, investing in structural, operational and cultural changes. I think all of that combined should support their growth goals over the …

The top 5 MassDevice stories of the week — August 28, 2020

As earnings season concludes and the COVID-19 pandemic roars on, medtech companies continue to find new ways to make waves.

This week’s top five MassDevice stories showcase how companies are operating in the “new normal,” as they look toward the post-pandemic future, whenever that may arrive. Strong quarterly earnings, big funding rounds and new innovations in COVID-19 treatment comprise some of this week’s list.

Want to hear more about the week’s top news? Executive editor Chris Newmarker and Tom Salemi will discuss during our DeviceTalks Weekly podcast. Without further ado, here’s this week’s MassDevice Top Five:

5. Medtronic’s recovery ‘faster than expected’ during Q1

Medtronic (NYSE:MDT) shares ticked up after the medtech giant came in well ahead of Wall Street projections for both earnings and revenues while posting profits of $491 million. Read the full story.

4. FDA clears Pelvital pelvic floor device

Pelvital announ…

FDA clears Pelvital pelvic floor device

Pelvital’s Flyte device. (Image courtesy of Pelvital)

Pelvital announced that it received FDA clearance for its Flyte device for treating those with stress urinary incontinence.

Minneapolis-based Pelvital touts Flyte as a first-of-its-kind, non-invasive, intravaginal home-use device designed to strengthen the pelvic floor muscles, which can help women with stress urinary incontinence, according to a news release.

Physicians at the Arctic University of Norway and other researchers in related fields originally developed Flyte before two clinical trials took place in Norway and the U.S., treating 200 patients and observing that most were dry or near dry after two to 12 weeks of treatment.

The company said Flyte is the only product to use an expanding area of treatment called mechanotherapy to treat pelvic floor muscle weakness, and the device will be made available to consumers in the U.S. s…